ProNAi Therapeutics Inc. (NASDAQ:DNAI) has received a consensus broker rating score of 2.50 (Hold) from the four analysts that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company.

Analysts have set a 12-month consensus target price of $2.50 for the company and are anticipating that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ProNAi Therapeutics an industry rank of 92 out of 265 based on the ratings given to related companies.

Several equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Wedbush cut shares of ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Monday, June 6th. SunTrust Banks Inc. cut shares of ProNAi Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $25.00 to $4.00 in a research report on Monday, June 6th. Finally, Jefferies Group cut shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $4.50 in a research report on Monday, June 6th.

ProNAi Therapeutics (NASDAQ:DNAI) traded up 2.570% during midday trading on Tuesday, hitting $1.836. 135,501 shares of the stock were exchanged. ProNAi Therapeutics has a one year low of $1.77 and a one year high of $29.81. The firm’s market capitalization is $55.68 million. The company has a 50 day moving average price of $1.89 and a 200 day moving average price of $3.90.

ProNAi Therapeutics (NASDAQ:DNAI) last announced its earnings results on Friday, August 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.05. Equities analysts anticipate that ProNAi Therapeutics will post ($1.32) EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of DNAI. A.R.T. Advisors LLC raised its position in shares of ProNAi Therapeutics by 35.3% in the first quarter. A.R.T. Advisors LLC now owns 16,100 shares of the company’s stock valued at $108,000 after buying an additional 4,200 shares during the period. Renaissance Technologies LLC raised its position in shares of ProNAi Therapeutics by 16.2% in the first quarter. Renaissance Technologies LLC now owns 45,300 shares of the company’s stock valued at $305,000 after buying an additional 6,300 shares during the period. Bridgeway Capital Management Inc. acquired a new position in shares of ProNAi Therapeutics during the second quarter valued at about $109,000. Ancora Advisors LLC acquired a new position in shares of ProNAi Therapeutics during the second quarter valued at about $132,000. Finally, Panagora Asset Management Inc. acquired a new position in shares of ProNAi Therapeutics during the second quarter valued at about $168,000. 35.25% of the stock is currently owned by institutional investors.

ProNAi Therapeutics Company Profile

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

5 Day Chart for NASDAQ:DNAI

Get a free copy of the Zacks research report on ProNAi Therapeutics (DNAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.